The Economic Impacts of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in an Australian Cohort.
Close, Shara, Marshall-Gradisnik, Sonya, Byrnes, Joshua et al. · Frontiers in public health · 2020 · DOI
Quick Summary
This Australian study calculated how much ME/CFS costs patients, their families, and the healthcare system. Researchers surveyed people with ME/CFS and found the total annual cost was approximately $14.5 billion, including medical visits, treatments, medicines, and lost income. The study shows that ME/CFS places a heavy financial burden on individuals and society.
Why It Matters
Understanding the economic burden of ME/CFS is critical for advocating for research funding, healthcare policy support, and patient services. This study provides concrete evidence of the substantial costs borne by patients and the healthcare system, which can inform government decisions about resource allocation and the need for better diagnostic and management strategies.
Observed Findings
Mean annual total cost of ME/CFS (healthcare and lost income) was approximately $14.5 billion across surveyed participants.
Participants attended an average of 10.6 specialist referral appointments and 12.1 general practitioner visits annually for ME/CFS management.
Highest direct out-of-pocket expenses were associated with medical practitioner attendance, diagnostic testing, natural/complementary medicines, and assistive devices.
Data were collected via survey between 2017 and 2019 from participants in a research registry database.
Diagnostic criteria applied included Canadian Consensus Criteria (CCC), International Consensus Criteria (ICC), and 1994 CDC Fukuda Criteria.
Inferred Conclusions
ME/CFS imposes a substantial economic burden on the Australian healthcare system and affected individuals and carers.
Improvement in disease understanding, diagnostic clarity, and management strategies could reduce overall healthcare costs and improve patient outcomes.
The high frequency of healthcare visits and out-of-pocket spending indicates significant unmet clinical needs and potential gaps in disease management.
Remaining Questions
How do healthcare costs and service utilization patterns differ across severity levels of ME/CFS?
What This Study Does Not Prove
This study does not establish causality or explain why ME/CFS costs are so high. It is based on self-reported data rather than objective billing records, which may introduce recall bias. The findings reflect Australian healthcare costs and patient demographics, so they may not apply to other countries with different healthcare systems.